NEW YORK (GenomeWeb) – Cancer Genetics on Thursday filed a shelf registration to offer up to $100 million in securities.

In its registration statement filed with the US Securities and Exchange Commission, the firm said that it may from time to time offer common stock, preferred stock, warrants, and overallotment purchase rights and units totaling up to $100 million in aggregate.

Net proceeds are intended for working capital and other general corporate purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.